US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Korro Bio, Inc.

12.71

-0.8800-6.48%

Post-market: 13.340.6300+4.96%17:20 EDT

Volume:75.87K

Turnover:975.62K

Market Cap:119.35M

PE:-1.35

High:13.63

Open:13.34

Low:12.60

Close:13.59

Loading ...

Overview Company News Filings

Korro Bio CFO Resumes Role After Temporary Medical Leave

MT Newswires Live

BRIEF-Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFO

Korro Bio Inc - Reappoints Vineet Agarwal as Principal Financial Officer

THOMSON REUTERS

Korro Bio Inc - Vineet Agarwal Ends Temporary Medical Leave as CFO - SEC Filing

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Korro Bio (KRRO)

Korro Bio Price Target Maintained With a $115.00/Share by HC Wainwright & Co.

Korro Bio’s Promising Growth: Buy Rating Backed by Positive KRRO-110 Trial Progress and Market Opportunities

RBC Capital Remains a Buy on Korro Bio (KRRO)

RBC Cuts Price Target on Korro Bio to $95 From $105, Keeps Outperform, Speculative Risk

MT Newswires Live

U.S. RESEARCH ROUNDUP-AT&T, Brighthouse Financial, ETSY

Korro Bio 2020 EPS $(9.37)

Press Release: Korro Reports Full Year 2024 Financial Results and Provides Business Updates

Krro-110 Receives Orphan Drug Designation From U.S. FDA for Alpha-1 Antitrypsin Deficiency

THOMSON REUTERS

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

BRIEF-Korro Bio Inc - CFO Vineet Agarwal Takes Temporary Medical Leave

Korro Bio Inc - CFO Vineet Agarwal Takes Temporary Medical Leave

THOMSON REUTERS

Korro Bio Inc - CEO Ram Aiyar Appointed Interim Principal Financial Officer

THOMSON REUTERS

Korro Bio announces initiation of dosing in its REWRITE study on KRRO-110

Korro Bio Announces Dosing of First Participants in Rewrite Phase 1/2a Study of Krro-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

THOMSON REUTERS

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KRRO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KRRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KRRO\",,,,,undefined,":{"symbol":"KRRO","market":"US","secType":"STK","nameCN":"Korro Bio, Inc.","latestPrice":12.71,"timestamp":1752264000000,"preClose":13.59,"halted":0,"volume":75868,"hourTrading":{"tag":"盘后","latestPrice":13.34,"preClose":12.71,"latestTime":"17:20 EDT","volume":268,"amount":3529.18,"timestamp":1752268821684},"delay":0,"floatShares":4888172,"shares":9390492,"eps":-9.437878,"marketStatus":"Market Closed","change":-0.88,"latestTime":"07-11 16:00:00 EDT","open":13.34,"high":13.625,"low":12.6,"amount":975623.2618,"amplitude":0.075423,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.437878,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1752480000000},"marketStatusCode":7,"adr":0,"listingDate":1570075200000,"exchange":"NASDAQ","adjPreClose":13.59,"postHourTrading":{"tag":"盘后","latestPrice":13.34,"preClose":12.71,"latestTime":"17:20 EDT","volume":268,"amount":3529.18,"timestamp":1752268821684},"volumeRatio":0.754942438524136},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KRRO\",,,,,undefined,":{"symbol":"KRRO","floatShares":4888172,"roa":"-29.82%","roe":"-60.22%","lyrEps":-9.369477,"volumeRatio":0.754942438524136,"shares":9390492,"dividePrice":0,"high":13.625,"amplitude":0.075423,"preClose":13.59,"low":12.6,"week52Low":10.29,"pbRate":"0.86","psRate":"24.76","week52High":98,"institutionHeld":0,"latestPrice":12.71,"eps":-9.437878,"divideRate":0,"volume":75868,"delay":0,"ttmEps":-9.437878,"open":13.34,"prevYearClose":38.07,"prevWeekClose":13.35,"prevMonthClose":12.49,"prevQuarterClose":12.49,"fiveDayClose":13.35,"twentyDayClose":14.87,"sixtyDayClose":12.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KRRO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522078183","title":"Korro Bio CFO Resumes Role After Temporary Medical Leave","url":"https://stock-news.laohu8.com/highlight/detail?id=2522078183","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522078183?lang=en_us&edition=fundamental","pubTime":"2025-03-27 22:28","pubTimestamp":1743085712,"startTime":"0","endTime":"0","summary":"Korro Bio  said Thursday that Chief Financial Officer Vineet Agarwal ended his temporary medical leave of absence and was reappointed by the board as principal financial officer of the company.Chief Executive Ram Aiyar will no longer be the interim principal financial officer, according to the company.The board also appointed Oliver Dolan as principal accounting officer, Korro said.Shares of the company were marginally higher in recent trading.Price: 17.83, Change: +0.06, Percent Change: +0.37","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","KRRO"],"gpt_icon":0},{"id":"2522306823","title":"BRIEF-Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2522306823","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522306823?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:18","pubTimestamp":1743081486,"startTime":"0","endTime":"0","summary":"BRIEF-Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFOMarch 27  - Korro Bio Inc KRRO.O:KORRO BIO INC - VINEET AGARWAL ENDS TEMPORARY MEDICAL LEAVE AS CFO - SEC FILINGKORRO BIO INC - REAPPOINTS VINEET AGARWAL AS PRINCIPAL FINANCIAL OFFICERFurther company coverage: KRRO.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1B9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRRO","BK4139"],"gpt_icon":0},{"id":"2522306853","title":"Korro Bio Inc - Reappoints Vineet Agarwal as Principal Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522306853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522306853?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:16","pubTimestamp":1743081409,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1B9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KRRO"],"gpt_icon":0},{"id":"2522068633","title":"Korro Bio Inc - Vineet Agarwal Ends Temporary Medical Leave as CFO - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522068633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522068633?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:16","pubTimestamp":1743081409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA1B9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRRO","BK4139"],"gpt_icon":0},{"id":"2520340834","title":"Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Korro Bio (KRRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520340834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520340834?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:40","pubTimestamp":1742467224,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avalo Therapeutics (AVTX – Research Report) and Korr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-avalo-therapeutics-avtx-and-korro-bio-krro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-avalo-therapeutics-avtx-and-korro-bio-krro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KRRO","HCSG","BK4137","AVTX","BK4139"],"gpt_icon":0},{"id":"2520434164","title":"Korro Bio Price Target Maintained With a $115.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520434164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520434164?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:28","pubTimestamp":1742466480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KRRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 06:28 ET (10:28 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRRO"],"gpt_icon":0},{"id":"2520902506","title":"Korro Bio’s Promising Growth: Buy Rating Backed by Positive KRRO-110 Trial Progress and Market Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2520902506","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520902506?lang=en_us&edition=fundamental","pubTime":"2025-03-19 19:15","pubTimestamp":1742382950,"startTime":"0","endTime":"0","summary":"Analyst Kostas Biliouris of BMO Capital maintained a Buy rating on Korro Bio (KRRO – Research Report), retaining the price target of $120.00. Kosta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/korro-bios-promising-growth-buy-rating-backed-by-positive-krro-110-trial-progress-and-market-opportunities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/korro-bios-promising-growth-buy-rating-backed-by-positive-krro-110-trial-progress-and-market-opportunities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KRRO","PRGS"],"gpt_icon":0},{"id":"2520790546","title":"RBC Capital Remains a Buy on Korro Bio (KRRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520790546","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520790546?lang=en_us&edition=fundamental","pubTime":"2025-03-19 18:37","pubTimestamp":1742380669,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi reiterated a Buy rating on Korro Bio (KRRO – Research Report) yesterday and set a price target of $95.00. The company...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-korro-bio-krro-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-korro-bio-krro-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","KRRO","BK4139"],"gpt_icon":0},{"id":"2520970073","title":"RBC Cuts Price Target on Korro Bio to $95 From $105, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2520970073","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520970073?lang=en_us&edition=fundamental","pubTime":"2025-03-19 18:24","pubTimestamp":1742379887,"startTime":"0","endTime":"0","summary":"Korro Bio (KRRO) has an average rating of buy and mean price target of $138.83, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KRRO"],"gpt_icon":0},{"id":"2520294796","title":"U.S. RESEARCH ROUNDUP-AT&T, Brighthouse Financial, ETSY","url":"https://stock-news.laohu8.com/highlight/detail?id=2520294796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520294796?lang=en_us&edition=fundamental","pubTime":"2025-03-19 15:35","pubTimestamp":1742369743,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-AT&T, Brighthouse Financial, ETSY March 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AT&T, B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nL4N3Q20KN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FERG","LU0472753341.HKD","BHF","LU1803068979.SGD","LU1778281490.HKD","LU2065170008.USD","LU0198837287.USD","LU2384288077.EUR","BK4534","BK4023","LU2125910336.SGD","CMG","LU1267930730.SGD","BK4567","LU0965509283.SGD","LU2360032135.SGD","IE00B5TLWC47.USD","RRC","KRRO","LU0861579265.USD","LU2458330169.SGD","BK4122","ETSY","PTMN","LU0354030511.USD","LU0672654240.SGD","LU1923621640.USD","TNDM","LU0158827948.USD","BK4507","LU0081259029.USD","LU2095319765.USD","LU0557290698.USD","BK4550","BK4585","PYXS","LU0109391861.USD","BK4515","LU0342679015.USD","LU1712237335.SGD","BK4220","BK4554","LU1633808545.USD","IE00BFXG1179.USD","T","LU0289961442.SGD","LU2125154778.USD","BK4082","LU2236285917.USD"],"gpt_icon":1},{"id":"2520779623","title":"Korro Bio 2020 EPS $(9.37)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520779623","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520779623?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:06","pubTimestamp":1742296011,"startTime":"0","endTime":"0","summary":"Korro Bio 2020 EPS $(9.37)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44373123/korro-bio-2020-eps-9-37","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Korro Bio 2020 EPS $(9.37)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRRO"],"gpt_icon":0},{"id":"2520623331","title":"Press Release: Korro Reports Full Year 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520623331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520623331?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:00","pubTimestamp":1742295600,"startTime":"0","endTime":"0","summary":"--  Completed dosing of first two cohorts in Phase 1/2a. REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin. --  U.S. Food and Drug Administration  Granted Orphan. programs, targeting two tissue types with a single. Clinical Advisory Board and key additions to board. \"KRRO-110 has best-in-class potential based on our preclinical data, and we are excited to potentially demonstrate this in PiZZ patients in the second half of 2025 with the interim data readout of REWRITE. We also anticipate announcing our second development candidate by the end of 2025. Our strategy of taking three development candidates in two tissue types with a single RNA-editing platform in the clinic by the end of 2027 will expand the possibilities of RNA editing, underscoring our commitment to progressing both our wholly owned and partnered programs.\". to progress enrollment in Australia, and potential expansion into. multiple jurisdictions, including the United States. An interim readout. is expected in the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","BK4006","BK4139","LU0882574139.USD","LU0267386448.USD","TM","CMC","LU0170899867.USD","03160","BK4555","RNA","BK4505","BK4585","LU0149725797.USD","KRRO","BK4099","BK4588","LU1363072403.SGD","IE00BKVL7J92.USD","LU0971096721.USD","BK4604","IE00BHPRN162.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2519803398","title":"Krro-110 Receives Orphan Drug Designation From U.S. FDA for Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2519803398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519803398?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:00","pubTimestamp":1741953601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nTUA2WMRZY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRRO","BK4139"],"gpt_icon":0},{"id":"2519280346","title":"KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2519280346","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519280346?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:00","pubTimestamp":1741953600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., March 14, 2025  -- Korro Bio, Inc.  , a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration  has granted orphan drug designation to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency .“Receiving orphan drug designation from the FDA underscores the growing need for new treatments for patients living with AATD,” said Kemi Olugemo, MD, Chief Medical Officer at Korro. “KRRO-110 has the potential to treat both liver and lung manifestations of AATD, and we are committed to addressing the unmet need and advancing this potentially best-in-class therapy for people living with AATD.”KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERATM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krro-110-receives-orphan-drug-120000852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNA","BK4585","BK4139","BK4588","KRRO","BK4505"],"gpt_icon":0},{"id":"2510366472","title":"BRIEF-Korro Bio Inc - CFO Vineet Agarwal Takes Temporary Medical Leave","url":"https://stock-news.laohu8.com/highlight/detail?id=2510366472","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510366472?lang=en_us&edition=fundamental","pubTime":"2025-02-12 06:49","pubTimestamp":1739314143,"startTime":"0","endTime":"0","summary":"BRIEF-Korro Bio Inc - CFO Vineet Agarwal Takes Temporary Medical LeaveKorro Bio Inc KRRO.O:KORRO BIO INC - CFO VINEET AGARWAL TAKES TEMPORARY MEDICAL LEAVEKORRO BIO INC - CEO RAM AIYAR APPOINTED INTERIM PRINCIPAL FINANCIAL OFFICERSource text: [ID:n0001193125-25-024305]Further company coverage: KRRO.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P212I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRRO"],"gpt_icon":0},{"id":"2510574213","title":"Korro Bio Inc - CFO Vineet Agarwal Takes Temporary Medical Leave","url":"https://stock-news.laohu8.com/highlight/detail?id=2510574213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510574213?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:21","pubTimestamp":1739308872,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P212I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRRO","BK4139"],"gpt_icon":0},{"id":"2510478357","title":"Korro Bio Inc - CEO Ram Aiyar Appointed Interim Principal Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2510478357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510478357?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:21","pubTimestamp":1739308872,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P212I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRRO","BK4139"],"gpt_icon":0},{"id":"2503304182","title":"Korro Bio announces initiation of dosing in its REWRITE study on KRRO-110","url":"https://stock-news.laohu8.com/highlight/detail?id=2503304182","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503304182?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:36","pubTimestamp":1736775375,"startTime":"0","endTime":"0","summary":"Korro Bio (KRRO) announced the initiation of dosing in its REWRITE study investigating KRRO-110 as a potential treatment for individuals with Alpha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/korro-bio-announces-initiation-of-dosing-in-its-rewrite-study-on-krro-110?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/korro-bio-announces-initiation-of-dosing-in-its-rewrite-study-on-krro-110?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KRRO","BK4139"],"gpt_icon":0},{"id":"2503586309","title":"Korro Bio Announces Dosing of First Participants in Rewrite Phase 1/2a Study of Krro-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2503586309","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503586309?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUA5RVM9N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KRRO"],"gpt_icon":0},{"id":"2503309402","title":"Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309402","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309402?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platform. Interim readout from REWRITE expected in the second half of 2025. Korro to advance additional pipeline programs towards clinical development. “We have evolved from a research organization to a clinical-stage drug development organization with our first participant in the REWRITE study recently dosed with KRRO-110. We have taken time to build our pipeline to demonstrate the versatility of RNA editing, building on data from other oligonucleotide programs,” said Ram Aiyar, PhD, President and CEO. “Over the next three years, we expect to take three product candidates into the clinic, in two tissue types with a single modular platform. This will be the crux of our 3-2-1 strategy through 2027. I am excited about the prospect that RNA editing holds beyond the treatment of rare genetic disease and applying our platform to highly prevalent diseases.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/korro-bio-announces-dosing-first-130000332.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","KRRO","BK4585","RNA","BK4139","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KRRO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"KRRO","fiscalQuarterEnding":"2025/03","expectedEps":-2.6,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":-2.49},{"market":"US","date":"2025-03-18","symbol":"KRRO","fiscalQuarterEnding":"2024/12","expectedEps":-2.33,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742270400000,"reportTimeType":"pre","actualEps":-2.26},{"market":"US","date":"2024-11-12","symbol":"KRRO","fiscalQuarterEnding":"2024/09","expectedEps":-2.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-2.26},{"market":"US","date":"2024-08-13","symbol":"KRRO","fiscalQuarterEnding":"2024/06","expectedEps":-2.4,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-2.43},{"market":"US","date":"2024-05-14","symbol":"KRRO","fiscalQuarterEnding":"2024/03","expectedEps":-2.36,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-2.44}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KRRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KRRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3,"buy":0.7,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7,"analysts":10,"updateTime":1745899200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KRRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KRRO","date":"2025-07-11","current":-1.459963,"percent":0.929293,"low":-8.894386,"twenty":-5.99384,"median":-4.62319,"eighty":-2.383248,"high":-1.160235,"avg":-4.494426,"sd":1.887383,"marketCap":127616786},"quantilePoints":[{"date":"2023-11-10","current":-4.581336,"twenty":-4.600294,"median":-4.593185,"eighty":-4.586076,"marketCap":328848276},{"date":"2023-11-17","current":-4.545683,"twenty":-4.815324,"median":-4.662668,"eighty":-4.586076,"marketCap":326289146},{"date":"2023-11-24","current":-4.263806,"twenty":-4.730727,"median":-4.581336,"eighty":-4.305029,"marketCap":306056020},{"date":"2023-12-01","current":-4.669353,"twenty":-4.669353,"median":-4.511145,"eighty":-4.263806,"marketCap":335166130},{"date":"2023-12-08","current":-5.29327,"twenty":-5.459276,"median":-4.605034,"eighty":-4.305029,"marketCap":379950915},{"date":"2023-12-15","current":-5.927214,"twenty":-5.596315,"median":-4.70004,"eighty":-4.344024,"marketCap":425455455},{"date":"2023-12-22","current":-5.775692,"twenty":-5.775692,"median":-5.29327,"eighty":-4.447639,"marketCap":414579150},{"date":"2023-12-29","current":-5.477103,"twenty":-5.763659,"median":-5.468189,"eighty":-4.46502,"marketCap":393146432},{"date":"2024-01-05","current":-5.57069,"twenty":-5.744941,"median":-5.477103,"eighty":-4.490422,"marketCap":399864150},{"date":"2024-01-12","current":-4.878811,"twenty":-5.700822,"median":-5.48323,"eighty":-4.552814,"marketCap":350201022},{"date":"2024-01-19","current":-4.570194,"twenty":-5.695474,"median":-5.467075,"eighty":-4.570194,"marketCap":328048548},{"date":"2024-01-26","current":-5.793518,"twenty":-5.702159,"median":-5.459276,"eighty":-4.579107,"marketCap":415858716},{"date":"2024-02-02","current":-5.903818,"twenty":-5.702159,"median":-5.475988,"eighty":-4.581336,"marketCap":423776026},{"date":"2024-02-09","current":-6.542219,"twenty":-5.793518,"median":-5.496043,"eighty":-4.605034,"marketCap":469600457},{"date":"2024-02-16","current":-6.005204,"twenty":-5.995177,"median":-5.561777,"eighty":-4.662668,"marketCap":431053553},{"date":"2024-02-23","current":-5.637539,"twenty":-6.009661,"median":-5.57459,"eighty":-4.668016,"marketCap":404662519},{"date":"2024-03-01","current":-5.381287,"twenty":-5.997182,"median":-5.57069,"eighty":-4.718452,"marketCap":386268768},{"date":"2024-03-08","current":-5.46819,"twenty":-5.954177,"median":-5.56679,"eighty":-4.734215,"marketCap":392506649},{"date":"2024-03-15","current":-6.597926,"twenty":-6.029715,"median":-5.57069,"eighty":-4.778761,"marketCap":473599099},{"date":"2024-03-22","current":-7.241897,"twenty":-6.148928,"median":-5.582946,"eighty":-4.827114,"marketCap":519823395},{"date":"2024-03-28","current":-8.749112,"twenty":-6.225581,"median":-5.594644,"eighty":-4.85118,"marketCap":710182879},{"date":"2024-04-05","current":-7.056213,"twenty":-6.445289,"median":-5.625283,"eighty":-4.87168,"marketCap":572766944},{"date":"2024-04-12","current":-7.760846,"twenty":-6.653602,"median":-5.643524,"eighty":-4.982426,"marketCap":629963419},{"date":"2024-04-19","current":-6.599635,"twenty":-6.850878,"median":-5.695474,"eighty":-5.142416,"marketCap":535705553},{"date":"2024-04-26","current":-6.686174,"twenty":-6.869775,"median":-5.765664,"eighty":-5.203025,"marketCap":542730135},{"date":"2024-05-03","current":-6.650761,"twenty":-6.964451,"median":-5.793518,"eighty":-5.219737,"marketCap":539855604},{"date":"2024-05-10","current":-6.269217,"twenty":-6.920952,"median":-5.915516,"eighty":-5.240905,"marketCap":508884843},{"date":"2024-05-17","current":-5.859151,"twenty":-6.869775,"median":-5.859151,"eighty":-5.274998,"marketCap":475317730},{"date":"2024-05-24","current":-5.495668,"twenty":-6.850878,"median":-5.84806,"eighty":-5.34608,"marketCap":445830598},{"date":"2024-05-31","current":-5.743893,"twenty":-6.8128,"median":-5.816278,"eighty":-5.412483,"marketCap":465967596},{"date":"2024-06-07","current":-5.114065,"twenty":-6.734223,"median":-5.793518,"eighty":-5.389162,"marketCap":414873438},{"date":"2024-06-14","current":-4.858019,"twenty":-6.694902,"median":-5.775692,"eighty":-5.295379,"marketCap":394101947},{"date":"2024-06-21","current":-4.102454,"twenty":-6.686174,"median":-5.755637,"eighty":-5.203025,"marketCap":332807503},{"date":"2024-06-28","current":-3.825833,"twenty":-6.685159,"median":-5.743893,"eighty":-5.149649,"marketCap":310366874},{"date":"2024-07-05","current":-4.380219,"twenty":-6.677519,"median":-5.73799,"eighty":-4.872237,"marketCap":355340861},{"date":"2024-07-12","current":-5.240945,"twenty":-6.652589,"median":-5.708166,"eighty":-4.858612,"marketCap":425166453},{"date":"2024-07-15","current":-5.618156,"twenty":-6.652132,"median":-5.702159,"eighty":-4.859205,"marketCap":455767311},{"date":"2024-08-02","current":-4.971182,"twenty":-6.651675,"median":-5.698816,"eighty":-4.859798,"marketCap":403282204},{"date":"2024-08-09","current":-4.113885,"twenty":-6.640451,"median":-5.660935,"eighty":-4.773204,"marketCap":333734802},{"date":"2024-08-16","current":-4.916432,"twenty":-6.613212,"median":-5.643524,"eighty":-4.733343,"marketCap":419376556},{"date":"2024-08-23","current":-4.817231,"twenty":-6.59861,"median":-5.625283,"eighty":-4.733343,"marketCap":410914634},{"date":"2024-08-30","current":-5.446229,"twenty":-6.597297,"median":-5.604672,"eighty":-4.737935,"marketCap":464568797},{"date":"2024-09-06","current":-4.658074,"twenty":-6.575014,"median":-5.590187,"eighty":-4.732471,"marketCap":397338364},{"date":"2024-09-13","current":-4.408437,"twenty":-6.520293,"median":-5.578489,"eighty":-4.665342,"marketCap":376044078},{"date":"2024-09-20","current":-4.196954,"twenty":-6.477243,"median":-5.57069,"eighty":-4.6075,"marketCap":358004377},{"date":"2024-09-27","current":-3.78816,"twenty":-6.457997,"median":-5.564005,"eighty":-4.555487,"marketCap":323133821},{"date":"2024-10-04","current":-3.412069,"twenty":-6.444854,"median":-5.520554,"eighty":-4.463176,"marketCap":291052909},{"date":"2024-10-11","current":-3.984381,"twenty":-6.396267,"median":-5.495668,"eighty":-4.391506,"marketCap":339871688},{"date":"2024-10-18","current":-8.722034,"twenty":-6.444854,"median":-5.494185,"eighty":-4.372675,"marketCap":743998188},{"date":"2024-10-25","current":-7.426973,"twenty":-6.575014,"median":-5.518326,"eighty":-4.380219,"marketCap":633528265},{"date":"2024-10-31","current":-6.633368,"twenty":-6.626621,"median":-5.552864,"eighty":-4.385863,"marketCap":565832892},{"date":"2024-11-08","current":-7.532715,"twenty":-6.647324,"median":-5.570133,"eighty":-4.416277,"marketCap":642548116},{"date":"2024-11-15","current":-5.302508,"twenty":-6.677519,"median":-5.57069,"eighty":-4.447647,"marketCap":465602621},{"date":"2024-11-22","current":-5.400663,"twenty":-6.652589,"median":-5.56679,"eighty":-4.448989,"marketCap":474221422},{"date":"2024-11-29","current":-5.554297,"twenty":-6.650761,"median":-5.56679,"eighty":-4.454222,"marketCap":487711719},{"date":"2024-12-06","current":-4.173725,"twenty":-6.633578,"median":-5.554297,"eighty":-4.447681,"marketCap":366486409},{"date":"2024-12-13","current":-4.690106,"twenty":-6.633368,"median":-5.55038,"eighty":-4.454222,"marketCap":411828797},{"date":"2024-12-20","current":-4.600486,"twenty":-6.599635,"median":-5.518326,"eighty":-4.476607,"marketCap":403959457},{"date":"2024-12-27","current":-4.39564,"twenty":-6.598268,"median":-5.495668,"eighty":-4.47213,"marketCap":385972394},{"date":"2025-01-03","current":-4.376436,"twenty":-6.597297,"median":-5.489358,"eighty":-4.431958,"marketCap":384286107},{"date":"2025-01-10","current":-4.013689,"twenty":-6.580078,"median":-5.474874,"eighty":-4.400759,"marketCap":352434016},{"date":"2025-01-17","current":-3.945407,"twenty":-6.549815,"median":-5.463733,"eighty":-4.371161,"marketCap":346438328},{"date":"2025-01-24","current":-4.049964,"twenty":-6.531256,"median":-5.447319,"eighty":-4.329948,"marketCap":355619225},{"date":"2025-01-31","current":-3.646675,"twenty":-6.482324,"median":-5.400974,"eighty":-4.264567,"marketCap":320207195},{"date":"2025-02-07","current":-3.864323,"twenty":-6.459999,"median":-5.376271,"eighty":-4.20066,"marketCap":339318449},{"date":"2025-02-14","current":-3.102554,"twenty":-6.448423,"median":-5.308909,"eighty":-4.176092,"marketCap":272429058},{"date":"2025-02-21","current":-3.056677,"twenty":-6.434147,"median":-5.302508,"eighty":-4.119313,"marketCap":268400706},{"date":"2025-02-28","current":-2.638451,"twenty":-6.340126,"median":-5.244267,"eighty":-4.093707,"marketCap":231677119},{"date":"2025-03-07","current":-2.367458,"twenty":-6.339446,"median":-5.203025,"eighty":-4.06287,"marketCap":207881733},{"date":"2025-03-14","current":-2.630983,"twenty":-6.269217,"median":-5.198397,"eighty":-4.049964,"marketCap":231021340},{"date":"2025-03-21","current":-2.460092,"twenty":-6.255885,"median":-5.114065,"eighty":-3.984381,"marketCap":205616953},{"date":"2025-03-28","current":-2.06468,"twenty":-6.247779,"median":-5.067789,"eighty":-3.960398,"marketCap":172568018},{"date":"2025-04-04","current":-1.656911,"twenty":-6.240921,"median":-5.016723,"eighty":-3.945407,"marketCap":138486304},{"date":"2025-04-11","current":-1.456959,"twenty":-6.236945,"median":-4.994706,"eighty":-3.88409,"marketCap":121774058},{"date":"2025-04-17","current":-1.512002,"twenty":-6.221793,"median":-4.974969,"eighty":-3.861976,"marketCap":126374620},{"date":"2025-04-25","current":-1.959087,"twenty":-6.206418,"median":-4.916432,"eighty":-3.824403,"marketCap":163742450},{"date":"2025-05-02","current":-2.066365,"twenty":-6.177673,"median":-4.874702,"eighty":-3.775951,"marketCap":172708852},{"date":"2025-05-09","current":-1.654409,"twenty":-6.170108,"median":-4.860984,"eighty":-3.687236,"marketCap":144613576},{"date":"2025-05-16","current":-1.555575,"twenty":-6.148652,"median":-4.836663,"eighty":-3.631696,"marketCap":135974324},{"date":"2025-05-23","current":-1.591026,"twenty":-6.130879,"median":-4.78968,"eighty":-3.512031,"marketCap":139073186},{"date":"2025-05-30","current":-1.260144,"twenty":-6.108373,"median":-4.78372,"eighty":-3.223328,"marketCap":110150471},{"date":"2025-06-06","current":-1.32675,"twenty":-6.061356,"median":-4.749297,"eighty":-3.117918,"marketCap":115972576},{"date":"2025-06-13","current":-1.50186,"twenty":-6.034499,"median":-4.735087,"eighty":-2.776295,"marketCap":131279078},{"date":"2025-06-20","current":-1.338568,"twenty":-6.030043,"median":-4.699133,"eighty":-2.705652,"marketCap":117005530},{"date":"2025-06-27","current":-1.325676,"twenty":-6.018574,"median":-4.677957,"eighty":-2.666335,"marketCap":115878671},{"date":"2025-07-03","current":-1.43418,"twenty":-6.003199,"median":-4.660916,"eighty":-2.628422,"marketCap":125363068},{"date":"2025-07-11","current":-1.459963,"twenty":-5.99384,"median":-4.62319,"eighty":-2.383248,"marketCap":127616786}],"updateTime":1752352489381}}}